` TFFP (TFF Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

TFFP
vs
S&P 500

Over the past 12 months, TFFP has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.

Back to TFFP Analysis

Stocks Performance
TFFP vs S&P 500

Loading
TFFP
S&P 500
Add Stock
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
TFFP vs S&P 500

Performance Gap Between TFFP and GSPC
HIDDEN
Show

Performance By Year
TFFP vs S&P 500

Loading
TFFP
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
TFF Pharmaceuticals Inc vs Peers

S&P 500
TFFP
LLY
JNJ
ROG
AZN
Add Stock
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

TFF Pharmaceuticals Inc
Glance View

Market Cap
288.6k USD
Industry
Pharmaceuticals

TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. The company is headquartered in Austin, Texas. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform. Its TFF platform is designed to enable solubility of poorly water-soluble drugs. Its drug candidates include TFF Voriconazole Inhalation Powder (VIP), TFF Tacrolimus Inhalation Powder (TIP) and Triple Combination. The company is developing TFF VIP to treat invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease. TFF VIP is being developed as an inhaled dry powder drug. The company is developing TFF TIP, a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. The company is developing Triple Combination, a dry powder drug combination to treat chronic obstructive pulmonary disease (COPD) and asthma. Its other dry powder products include Inhaled SARS-CoV2 Monoclonal Antibody, Niclosamide Inhalation Powder, Cannabidiol (CBD) and Vaccines.

TFFP Intrinsic Value
Not Available
What is Intrinsic Value?
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.